Search

Alvotech SA

Slēgts

SektorsVeselības aprūpe

5.85 10.38

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

5.79

Max

5.95

Galvenie mērījumi

By Trading Economics

Ienākumi

-68M

-67M

Pārdošana

-93K

106M

P/E

Sektora vidējais

42.4

56.432

EPS

-0.11

Peļņas marža

-63.175

Darbinieki

1,279

EBITDA

-54M

-1.5M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+19.25% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 11. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

461M

1.8B

Iepriekšējā atvēršanas cena

-4.53

Iepriekšējā slēgšanas cena

5.85

Ziņu noskaņojums

By Acuity

51%

49%

250 / 339 Rangs Healthcare

Alvotech SA Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 18. sept. 23:01 UTC

Alvotech SA is trading higher in after-market hours, maintaining a position significantly above its 20-day moving average after four consecutive sessions of gains.

2026. g. 17. sept. 22:11 UTC

Alvotech SA is advancing in after-market trading, continuing its upward trend and remaining well above its 20-day moving average.

2026. g. 16. sept. 23:01 UTC

Alvotech SA is trading higher in after-market hours, remaining above its 20-day moving average despite a notable decline from an early session high.

2026. g. 14. sept. 20:08 UTC

Alvotech SA shares are lower today, continuing a decline that began earlier in the session, reversing recent gains from the past three days.

2026. g. 11. sept. 19:36 UTC

Alvotech SA shares are higher, reflecting intraday strength amid broader market dynamics, including U.S. Consumer Price Index data influencing inflation expectations.

2026. g. 10. sept. 20:07 UTC

Alvotech SA shares are higher as the European Central Bank raised interest rates by 25 basis points, influencing market dynamics. No specific company news was identified.

2026. g. 9. sept. 20:07 UTC

Alvotech SA shares are lower today, marking a fourth consecutive decline. The broader market faces pressure from rising crude oil prices above $100 per barrel.

2026. g. 8. sept. 20:03 UTC

Alvotech SA shares are lower today, having declined since Friday's close. The stock reached a session low before partially recovering.

2026. g. 3. sept. 19:56 UTC

Alvotech SA shares are trading roughly flat, with no specific news identified. The stock remains significantly above its 20-day moving average.

2026. g. 2. sept. 21:02 UTC

Alvotech SA shares are lower in after-market hours, continuing recent downward momentum amid a disappointing ADP report on slower job growth.

2026. g. 1. sept. 20:08 UTC

Alvotech SA shares are trading lower amid broader market trends. Rising oil prices and inflation concerns are influencing market expectations for interest rate hikes.

2026. g. 31. aug. 20:03 UTC

Social Media
News

Alvotech SA shares are higher after the FDA accepted its Biologics License Application for AVT80, a proposed interchangeable biosimilar to Entyvio.

2026. g. 28. aug. 20:07 UTC

News

Alvotech SA shares are rising after Bank of America initiated coverage with a Buy rating and a $7 price target.

2026. g. 26. aug. 19:51 UTC

Alvotech SA shares are lower today amid broader market pressures. Inflationary concerns from recent PCE data may influence Federal Reserve policy discussions.

2026. g. 25. aug. 19:16 UTC

Alvotech SA shares are lower today after a morning peak. No specific news has been identified to explain the price movement.

2026. g. 24. aug. 23:16 UTC

Alvotech SA shares are trading roughly flat in after-market hours. The stock has gained significantly over the past month, remaining above its 20-day moving average.

2026. g. 21. aug. 19:51 UTC

News
Social Media

Alvotech SA has signed a licensing agreement with Lotus Pharmaceutical for two biosimilars, potentially generating $150 million in payments, as shares trade higher.

2026. g. 20. aug. 20:02 UTC

News

Alvotech reaffirms 2026 revenue guidance amid Q2 revenue decline.

2026. g. 19. aug. 23:01 UTC

Event
News

Alvotech SA reaffirmed its 2026 sales guidance of $650 million to $700 million, boosting investor sentiment and driving shares higher in after-market trading.

2026. g. 18. aug. 19:16 UTC

Alvotech SA shares are higher today, maintaining a cumulative gain since Monday. The stock is above its 20-day moving average and near its one-month high.

2026. g. 17. aug. 21:02 UTC

Alvotech SA shares rose during after-market hours, reaching a high of 2.84%. The price is above its 20-day moving average and near a one-month high.

2026. g. 14. aug. 19:56 UTC

Alvotech SA shares are trading roughly flat amid broader market sentiment influenced by a decline in U.S. retail sales for July.

2026. g. 13. aug. 20:06 UTC

Alvotech SA shares are higher during Thursday's session, continuing an upward trend since Wednesday's close, trading above its 20-day moving average.

2026. g. 12. aug. 19:31 UTC

Alvotech SA shares are trading higher, reflecting market optimism after recent inflation data showed core CPI aligned with forecasts. No specific company news was identified.

2026. g. 11. aug. 19:26 UTC

News

Alvotech's Reykjavik facility receives Voluntary Action Indicated status from the FDA, allowing advancement of multiple Biologics License Applications. Shares are trading higher.

2026. g. 10. aug. 20:06 UTC

News

Alvotech SA will release its financial results for the first half of 2026 on August 19, after the U.S. market close. Shares are little changed.

2026. g. 6. aug. 20:06 UTC

Alvotech SA shares are higher today, trading above their 20-day moving average and near the upper end of their one-month range. No specific news was identified.

2026. g. 5. aug. 19:56 UTC

Alvotech SA shares are lower during Wednesday's session, continuing a decline since Tuesday's close amid broader market trends and falling oil prices.

2026. g. 4. aug. 19:52 UTC

Alvotech SA shares are higher today, supported by declining crude oil prices easing inflation concerns. The stock remains above its 20-day moving average.

2026. g. 3. aug. 19:51 UTC

Alvotech SA shares are lower today, reflecting a sharp decline despite a brief rebound earlier in the session. No specific news was identified for the drop.

Salīdzinājums

Cenas izmaiņa

Alvotech SA Prognoze

Cenas mērķis

By TipRanks

19.25% augšup

Prognoze 12 mēnešiem

Vidējais 7 USD  19.25%

Augstākais 8 USD

Zemākais 6 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Alvotech SA — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

3 ratings

3

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

250 / 339 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Alvotech SA

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.